Moderna Inc.
Moderna, Inc. Approves Major Corporate Governance Amendments at Annual Meeting
Summary
Moderna, Inc. successfully passed significant corporate governance amendments at its 2024 Annual Meeting of Stockholders, including provisions allowing shareholders holding at least 20% of the company's outstanding shares to call a special meeting and changes to the Certificate of Incorporation to provide for the exculpation of executive officers as permitted by Delaware law. These amendments, which were subject to stockholder approval, became effective upon the Company filing them with the Delaware Secretary of State on May 8, 2024. Additionally, the Board approved corresponding amendments to the Company's By-laws, which also became effective on May 8, 2024.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement